A SPAC deal with RA Capital–sponsored RACC is expected to yield ~$175 million gross, including a fully backstopped trust and PIPE/SAFE financing, with closing targeted by end of 2026. Rugonersen, an ...

Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...

Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...

Oak Hill Bio secures $175 million through a SPAC combination with RA Capital, Apnimed set terms for a $150 million IPO, and CORE Biomedicine closes a $21 million Series A. In today's Pharmaceutical ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...

Since then, that mindset has continued to grow at AbbVie.

In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a supply chain expert discusses how China's export ...

Narrow votes supported compounding of BPC-157, KPV, and TB-500 (8-6; one abstention) and MOTS-c (7-5; two abstentions), without constituting FDA approval or demonstrated clinical benefit. Regulatory ...

Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...

Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or ...